Nasdaq · Biotech stocks database
MGX — Metagenomi Therapeutics Inc. ☆
MGX (Metagenomi Therapeutics Inc.) stock: $0.71, $26.8M market cap, $120.7M cash, -$93.9M EV, $31.5M fully diluted market cap. Data from Fully Diluted's biotech stocks database.
Overview
Catalysts
Assets
Pipeline
Trials
Holders
News
What they do
We are an in vivo genome editing company capitalizing on our proprietary technologies to create curative genetic medicines for patients. We were founded on the science of metagenomics, the study of genetic materials recovered from the natural environment, to discover and develop a suite of novel gene editing tools potentially capable of correcting any type of genetic mutation found anywhere in the human genome.
Source: 10-K FY2025 via SEC EDGAR
Balance sheet
Cash $120.7M Debt $0.0M Net cash $120.7M Enterprise value -$93.9M Basic shares 37.8M shares Fully diluted shares 44.4M shares Fully diluted market cap $31.5M Cash per share $3.19 Quarterly burn $19.5M Cash runway 6.2 quarters
Cash figures as of 2026-06-30. Database snapshot: 2026-11-07.
Share structure
Cap table as of 2026-06-30.
Price history Loading MGX daily closes…
Loading price history…
Next catalyst MGX-001 · Est. Nov 15, 2026 · quarter midpoint · guided Now All upcoming catalysts →
Upcoming catalysts Expected Drug Phase Indication Mgmt guide GUIDED Est. Nov 15, 2026 Now quarter midpoint
MGX-001Global clinical program (IND submission)
Not disclosed Global ( ) Q4 2026
Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Full readout calendar →
Asset data not yet available for this company.
No lead program on file for this company.
No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.
Specialist fund holders Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.
None of the tracked specialist funds reported a position in the latest 13F snapshot.
Fully Diluted · Free biotech stocks database. Figures are sourced from SEC filings and company disclosures; not investment advice.